Rubicon Research Ltd

Rubicon Research Limited trading window closed from Oct 1, 2026 in connection with unaudited financial results for quarter and half year ended Sep 30, 2026; window will reopen 48 hours after results are declared and submitted to stock exchanges.

Target Company

• Rubicon Research Limited.

Disclosing Party

• Acquirer/Seller: General Atlantic Singapore RR Pte. Ltd.; promoter of Rubicon Research Limited.

Transaction Type

• Disposal of 14,000,000 equity shares by promoter seller.

Pre-Transaction Holding

• Pre-transaction holding: 5,92,58,360 shares (35.79%).
• Encumbrances: NA.

Transaction Details

• Shares sold: 14,000,000 equity shares (8.45% of voting capital); mode: on-market.

Post-Transaction Holding

• Post-transaction holding: 4,52,58,360 shares (27.34%).

Dates of Transaction

• Dates: 25 August 2026 and 26 August 2026.

Share Capital Context

• Equity share capital before/after: INR 16,55,31,908; diluted post-transaction: INR 16,71,56,286.

Transaction overview

• Target: Rubicon Research Limited; Acquirer/Seller: General Atlantic Singapore RR Pte. Ltd.; promoter of the TC.
• Transaction Type: Disposal of shares via on-market sale.
• Mode: On-market sale.
• Dates: 25 August 2026 and 26 August 2026.

Holding and capital details

• Pre-holding: 5,92,58,360 shares; 35.79% VR; encumbrances: NA.
• Post-holding: 4,52,58,360 shares; 27.34% VR.
• Shares sold: 1,40,00,000 (8.45% of voting capital).
• Total diluted share capital after: INR 16,71,56,286.
• Equity share capital before/after: INR 16,55,31,908.
• Post-diluted holding: 27.07%.

Financial Performance

• Revenue from operations: INR 5,343 million, up 52% YoY.
• Gross profit: INR 3,543 million.
• PAT: INR 848 million; up 96% YoY; EPS: INR 5.08.
• USD revenue: USD 55 million; up 32% YoY; slight sequential dip due to margin measures.
• Arinna impact: revenue ~INR 12 crores; EBITDA impact not material.
• Gross margin: 67.7% (up ~140 bps sequential); EBITDA margin: 24.2% (up from 23.1%).
• Top-5 products: 39% of revenue; Top-10: 55%.

Operations & Portfolio Update

• Arinna acquisition closed in April; revenue impact ~INR 12 crores; EBITDA impact not material.
• USD revenue includes products from Arinna; R&D productivity commentary unchanged.
• R&D spend: 10.9% of consolidated operating revenue in the quarter.
• R&D productivity is ~5.5x on rolling three-year basis (excludes Arinna).
• Two product approvals in the quarter; commercialization rate at 88%.
• 63 products were at advanced stages of development per DRHP; portfolio evolution shown in slides.
• Pithampur FDA 483: two observations; response filed; FDA approval anticipated; ramp-up from Q1 CY2027.

Capital & Cash Flow

• Capital employed: INR 14,778 million; cash & cash equivalents: INR 2,408 million.
• Net working capital days: 114 vs 126 on 31-Mar-2026.
• Operating cash flow before WC changes: INR 1,390 million; cash flow from operations: INR 285 million.
• Pithampur site headroom: large expansion potential; current utilization ~5–6 acres of ~30 acres.
• East Brunswick, USA facility acquired; purchase price USD 2.9 million; onshore manufacturing benefits.

Guidance & Outlook

• FY27 EBITDA margin guided higher to 23%.
• R&D spend target: INR 500 crores over nine quarters (FY26-FY28); INR 251 crores spent in five quarters.
• Current R&D run-rate ~INR 60 crores per quarter; on track to meet INR 500 crores by Q1 FY28.
• FY22 R&D spend ~39.5% of revenue; normalized to industry-leading 10–11%.
• US facility investment expected to be margin-accretive; no gross-margin dilution; focus on differentiated products.

Q&A Highlights

• Approvals pace discussed; portfolio strategy remains consistent with plan; emphasis on conservative revenue forecasts.
• US footprint viewed as strategic; onshore manufacturing and government/VA opportunities; margin impact expected to be neutral or accretive.
• Headroom at Pithampur noted; substantial capacity expansion potential within existing site.

Issue overview

• IPO of equity shares (fresh issue) disclosed; net proceeds not disclosed.
• Total issue size disclosed; no undersubscription reported.
• Main use: debt repayment, inorganic growth, and general corporate purposes.

Utilisation of proceeds

• Utilisation as per offer document: Yes; board-approved timeline extension.
• Deviation from disclosed objects: Not observed.
• Prepayment of borrowings: Ongoing; extension approved by Board.
• Funding inorganic growth: Ongoing; no material change reported.
• Unutilised proceeds: parked in fixed deposits, monitoring and escrow accounts totaling 830.67 million.

GCP utilisation

• GCP utilisation: 160 million for Corporate Advance Tax.

Governance and approvals

• Board-approved extension for utilization; MA notes no further approvals required.

CFO appointment and senior management transition

• Rohit Saraogi appointed CFO designate; Nitin Jajodia moves to Chief Commercial Officer.
• Effective August 14, 2026; subject to applicable approvals.
• Reason: leadership transition to support growth.

Chairman re-appointment

• Venkat Changavalli re-appointed Chairman; term Sep 18, 2026 to Jun 10, 2027.
• Independent Director extension co-terminus with first term.
• Disclosure: no related-party or other director relationships disclosed.

Business Overview

• Rubicon shifting from contract services toward specialty pharma with US footprint.
• Arinna acquisition consolidated; FY27 Q1 revenue reflects impact.
• Acquired East Brunswick, NJ manufacturing facility for USD 2.9 million.
• Pithampur FDA inspection resolved; ramp-up planned from CY2027.
• New US manufacturing footprint enables specialty/high-value products and US government demand.
• CFO-designate Rohit Saraogi; CFO transition of Nitin Jajodia to CCO.

Key Operational Highlights

• Q1 FY27 revenue ₹5,343 Mn, up 51.6% YoY.
• Gross profit ₹3,543 Mn; gross margin 67.7%.
• Operating EBITDA ₹1,291 Mn; margin 24.2%.
• Two product approvals in Q1 FY27; 88% of approvals commercialised.
• USD revenue ₹55 Mn in Q1 FY27; YoY +32%.
• Cash flow from operations ₹285 Mn; GST refunds delayed cash flow.

Financial Performance

• PAT ₹848 Mn; EPS ₹5.08; solid earnings growth post-Arinna.
• R&D expense 580 Mn; 10.9% of revenue; continued high R&D intensity.
• ROACE steady at 36% annualized; reinforcing high-return profile.
• Total equity ₹13,913 Mn; borrowings ₹3,272 Mn; cash ₹2,408 Mn.

Capital Structure & Liquidity

• Debt financing mainly for working capital; limited equity raised since IPO.
• IPO completed Oct 2025; minimal equity dilution since inception.
• Sources of funds ₹17,186 Mn as of 30-Jun-26.

Strategic Priorities & Outlook

• FY27 Operating EBITDA margin guided to at least 23%.
• R&D spend guidance: INR 5,000 Mn+ over 9 quarters; supports long-term growth.
• NJ site focuses on specialty/high-value products; commercialization targeted CY2027.
• Regulatory moat via FDA QMM program; ongoing quality culture.

Risks & Mitigation

• GST refunds delay impacted cash flows; normalization expected in Q2 FY27.
• Geopolitical input-cost increases; mitigated by product mix and cost controls.
• R&D productivity risk; maintained via internal and external partnerships.

Governance & Leadership

• CFO designate Rohit Saraogi; CFO transition of Nitin Jajodia to CCO.
• Board approvals implemented; leadership bandwidth strengthened for growth.

Financial results approved

• Unaudited standalone and consolidated results for quarter ended 30-Jun-2026 approved.
• Limited Review conducted by statutory auditors.
• Standalone revenue ₹4,277m; PAT ₹824.5m; Consolidated revenue ₹5,343m; PAT ₹847.8m.

IPO proceeds extension

• Timeline for utilisation of unutilised IPO proceeds extended to 31-Mar-2027.

Amalgamation plan

• Scheme of Amalgamation with Kia Health Tech Private Limited approved; filed with RoC; not yet effective.

Acquisition - Arinna Lifesciences

• Acquired 85% stake in Arinna Lifesciences for ₹1,759.17m; completion 30-Apr-2026; results included from acquisition date.

Post-quarter developments

• AdvaGen Holdings' Inc. acquired a New Jersey manufacturing facility for USD 2.9 million.

Business structure

• Group operates in a single segment: Sale of Pharmaceuticals products.

Financial snapshot

• Revenue from operations: INR 17,540 million (FY25-26 standalone).
• EBITDA: INR 4,080 million; EBITDA margin 23.16%.
• PAT: INR 2,467 million; PAT margin 14.01%.
• Total income (standalone): INR 17,616.83 million; Net worth INR 12,888 million.
• ROCE (pre-tax): 24.67%.
• R&D expenditure: INR 1,989 million; R&D intensity 11.34%.
• Total employees: 1,303; Women: 17.11%.
• IPO completed Oct 2025; net IPO proceeds ₹4,712.74 million.
• ₹3,236.46 million utilized; ₹1,476.28 million unutilised.
• Final dividend: INR 1.50 per share; ~₹25 crore payout.
• Dividend payout ratio: 13.29% of standalone profit after tax.
• Arinna Lifesciences 85% stake acquired post-year; CNS expansion.

Growth & strategy

• IPO completed Oct 2025; listed on BSE and NSE.
• Arinna Lifesciences 85% stake acquired in Apr 2026; CNS market entry in India.
• Pithampur facility acquired FY26; production ramp-up targeted CY27.
• AimRx 3PL acquisition strengthens US distribution network.
• Investments in Neuronasal and GEn1E Lifesciences to augment pipeline.
• US/reg regulatory emphasis; 98% revenue from regulated USD markets.
• Specialty products contribute 32.3% of gross profit; portfolio expanding.
• 12 FDA approvals in FY26; 24 USFDA reviews of pipeline products.
• R&D productivity and commercialisation pipeline drive long-term growth.

Manufacturing & operations

• Three manufacturing sites: Ambernath, Satara, Pithampur; multi-dosage forms and drug-device combos.
• Pithampur site ramps up to support high-potency and hormone products.
• Canada R&D facility achieved FDA zero-observation; Thane HQ also zero-observation.
• Global regulator inspections reflect strong quality and compliance culture.
• FY26: Solar PV installations contributing renewable energy; ZLD wastewater management.
• FY26: ~5.05 billion units produced; in-house and outsourced manufacturing mix maintained.

IPO, capital structure & capital allocation

• IPO proceeds partly used for debt repayment and inorganic growth.
• Arinna acquisition expands CNS capability and domestic branded portfolio.
• Discipline in capex: CAPEX follows demand; Pithampur ramps up to reduce outsourcing.
• Final dividend proposed; payout policy aligned with shareholder value.
• Adjusted net debt to equity improved to near-zero; balance sheet strengthened post-IPO.

Governance & risk

• Board: Independent Director Pradnya Saravade joined Feb 3, 2026; Anand Agarwal resigned Feb 3, 2026.
• KMPs include MD, CEO, CFO, Company Secretary; governance strengthened post-IPO.
• Auditors: Deloitte Haskins & Sells; internal Protiviti; secretarial BNP & Associates.
• Robust risk management framework; Risk Management Committee oversees ESG and cyber risk.
• Management and Board regularly review KPIs; 10 Audit Committee meetings in FY26.

ESG, CSR & environment

• CSR spend: INR 16.13 million; impact on 2,485 beneficiaries.
• ZLD wastewater system; renewable energy initiatives and water conservation measures.
• Renewable energy: Solar PV at multiple sites; 4 MW group captive solar project planned by Oct 2026.
• Waste management: hazardous waste co-processing; waste recycling and segregation.
• Employee health, safety and DEI: 17.11% women; DEI initiatives; learning through Rubicon Academy.

Outlook & risks

• R&D led growth; nine-quarter plan with INR 5,000 million+ R&D spend guidance for FY26-FY28.
• Portfolio expansion in CNS, CVS and specialty segments; US regulatory opportunities ahead.
• Patents cliff in US generics offers growth; continue to differentiate through drug-device combos.
• Geographic expansion to regulated markets beyond US; continued focus on scale, quality, and productivity.